the spreading of the autoimmune response, as demonstrated using IFNa/bR-null mice. Muscle infiltration was maintained in the injected muscle up to the end of the follow-up period.
Conclusion. TLR-7/8 activation is necessary to induce and maintain a systemic autoimmune response targeting the skeletal muscle. This experimental autoimmune myositis model reproduces many characteristics of human idiopathic inflammatory myopathies and may represent a tool for preclinical studies.
Idiopathic inflammatory myopathies (IIMs) are the largest group of myopathies (1) . Various classifications have been proposed (2) (3) (4) (5) . Myositis-specific autoantibodies are found, including antisynthetase antibodies, such as those specific for anti-histidyl-transfer RNA synthetase (anti-HisRS; also referred to as anti-Jo-1) (6) (7) (8) . Histologic features comprise endomysial, perimysial, or perivascular infiltration by inflammatory cells (including autoreactive T lymphocytes), expression of myofiber major histocompatibility complex (MHC) class I molecules, muscle injury and regeneration, tissue remodeling with fibrosis, and fat deposition (1) . Various disease mechanisms have been proposed, but the pathogenesis of IIM remains unclear (9) (10) (11) . Therapy is mostly based on glucocorticoids and/or nonselective immunosuppressive drugs, with elevated toxicity and often limited efficacy (12, 13) .
Viral infection might influence the immunogenicity of muscle autoantigens, possibly via aberrant generation of cytokines with adjuvant actions (11, 14) . For example, type I interferon (IFN)-regulated proteins are up-regulated in the muscle and skin tissue of IIM patients, and the levels of their expression correlate with disease activity (15) (16) (17) . Myofiber precursors and regenerating fibers play a key role as a source of IIM autoantigens (18) (19) (20) , and type I IFN induces myoblast MHC class I expression and mitochondrial function in vitro (21, 22) . A multicenter clinical trial is ongoing to evaluate the efficacy of the anti-IFNa monoclonal antibody sifalimumab in patients with IIM (23) . Type I IFN induction might depend on the activation of Toll-like receptors (TLRs) (24) . IFNs and various TLRs are indeed up-regulated in infiltrating leukocytes and muscle tissue of patients with IIM (21, (25) (26) (27) (28) .
To investigate whether the TLR/type I IFN pathway is causally involved in IIM development, we explored the long-term effects of TLR-7/8 activation in a well-characterized experimental model of myositis induced by intramuscular injection of a fragment of the mouse HisRS antigen (29) (30) (31) , which elicits focal and transient autoimmunity and muscle inflammation (29, 30, 32, 33) . In this study we demonstrated that mouse myositis was exacerbated and sustained when the autoantigen was injected in the presence of R-848, a cell-permeable and specific TLR-7/8 agonist (34) . Type I IFN was responsible for most actions of R-848, including prolonged autoantibody generation, spreading of muscle inflammatory reaction, and fiber MHC class I overexpression.
MATERIALS AND METHODS
Mice and treatments. Wild-type C57BL/6 mice (8-10 weeks old; Charles River) or syngeneic type I IFN receptordeficient (IFNa/bR-null) mice (a gift from Dr. Iannacone Milano, Ospedale San Raffaele Scientific Institute) (35) were housed in a pathogen-free facility and treated in accordance with European Union guidelines, with the approval of the local institutional ethics committee (Institutional Animal Care and Use Committee #742). The muscles of wild-type and untreated IFNa/bR-null mice revealed no signs of inflammation, necrosis, or regeneration. Myositis was induced by intramuscular injection of a recombinant amino-terminal fragment portion (residues 1-151) of the murine HisRS molecule, as previously described (30) . Briefly, both gastrocnemius muscles were injected with the antigen (0.2 mg/mouse in 50 ll of phosphate buffered saline [PBS] ) and Freund's incomplete adjuvant (IFA) in the presence or absence of R-848 (1 mg/kg; InvivoGen) (34) . Sham-treated mice received either PBS plus IFA or R-848 plus IFA.
Histologic grading of inflammation. After mice were killed, muscles (gastrocnemius, quadriceps, anterior tibialis, and triceps brachii) were rapidly isolated and frozen. Serial cryosections of mouse muscle of 8-10 lm were cut at a distance of 300-400 lm, and 6-8 sections from each sample were stained with hematoxylin and eosin and examined using an Axioskop microscope equipped with an AxioCam ERc 5s camera (Zeiss). Two trained investigators (CS and AM) who were blinded with regard to study group scored all mouse muscle sections independently for mononuclear cell infiltration. A mean score was calculated for each sample based on the intensity and distribution of inflammatory cell infiltration, where 0 = no inflammatory lesions; 1 = small inflammatory lesions (<10% of the section area infiltrated with mononuclear cells) in an endomysial distribution with no perimysial involvement, 2 = medium inflammatory lesions (10-30% of the section area infiltrated with mononuclear cells) with either endomysial or perimysial distribution, 3 = large inflammatory lesions (30-50% of the section area infiltrated with mononuclear cells) with either endomysial or perimysial distribution, and 4 = diffuse and extensive lesions (>50% of the section area infiltrated with mononuclear cells) in which both endomysial and perimysial inflammatory foci are present.
Histologic analysis and immunofluorescence staining. To evaluate fibrosis, mouse tissue was stained with sirius red (36) . Briefly, frozen sections were fixed and incubated with 0.1% sirius red dye in picric acid for 1 hour and washed, dehydrated, and mounted. Images were captured using an Axioskop microscope. Immunofluorescence staining was carried out on fixed sections (4% paraformaldehyde or cold acetone for anti-CD3) using rat anti-CD3 (1:100; Abcam), anti-CD68 (1:300; Abcam), anti-B220 (1:100; BD Biosciences), and anti-MHC class I (1:200; Abcam) antibodies, as previously described (20) . Unrelated isotypematched antibodies were used as controls. Images were captured using a PerkinElmer Ultraview ESR confocal laser scanning microscope. Linear adjustments of the images were made using Adobe Photoshop CS4.
Autoantibody detection and quantification. HisRS IgG antibodies in mouse serum (1:20,000 or 1:50,000 dilutions) were measured by enzyme-linked immunosorbent assay (ELISA) as previously described (29, 30) . Serial serum dilutions (1:1,000-1:50,000) were used for ELISA, and the figures show the serum dilution at which average optical density values in treated mouse serum were significantly different from those in vehicle-treated mouse serum. Serum from a single animal was measured in duplicate.
Retrieval of CD45+ muscle-infiltrating leukocytes. Infiltrating cells were retrieved by enzymatic digestion using type II collagenase (200 units/ml; Sigma) at 37°C for 40 minutes followed by CD45+ leukocyte retrieval by magnetic sorting (Miltenyi Biotec). Murine gastrocnemius muscles were pooled and digested. The purity of CD45+ fractions (80-90%) was verified by flow cytometry (Canto 4.2.2 flow cytometer with Diva Software by BD Biosciences) using a PerCP-conjugated anti-CD45 antibody (clone 30-F11, 1:100) (BD Biosciences). For characterization of inflammatory cells, the following antibodies were used: phycoerythrin (PE)-Cy7-conjugated anti-CD3 (clone 145-2C11; BD Biosciences) for T lymphocytes, fluorescein isothiocyanate-conjugated anti-220 (clone RA3-6B2; BD Biosciences) for B lymphocytes, allophycocyanin (APC)-Cy7-conjugated anti-F4/80 (clone BM8; BioLegend) for macrophages, PE-conjugated anti-CD8 (clone 53-6.7; BD Biosciences), and APC-conjugated anti-CD4 (clone GK1.5; BioLegend). Analysis was performed using FlowJo software (Tree Star).
Isolation and treatment of myogenic precursors and single fibers. Myogenic precursors were isolated from 8-weekold mice by enzymatic digestion of leg muscles with a mixture of type II collagenase (500 units/ml; Worthington) and Dispase (2.4 units/ml; Gibco Life Technologies) dissolved in PBS (5 ml/ mouse). Cells were retrieved and cultured for 2-3 days on Matrigel-coated dishes until they reached confluence (20) . Cells were then cultured for an additional 24 hours in Dulbecco's modified Eagle's medium (DMEM) containing 2% bovine serum albumin to induce fusion. Myotubes were treated with 10 lg/ml of R-848, 2,000 units/ml of recombinant murine IFNa (BioLegend), 100 ng/ml of IFNc (PeproTech), or vehicle for an additional 24 hours (for isolation of messenger RNA) or 48 hours (for immunofluorescence staining). To verify the purity of myotube preparations, skeletal myosin expression was evaluated by immunofluorescence staining using a specific TLR-7/8 IN EXPERIMENTAL MYOSITISantibody (MF-20; Developmental Studies Hybridoma Bank). Nuclei were stained with Hoechst. Consistently, >80% of total nuclei were in myosin-positive structures.
For single fiber isolation, murine gastrocnemius muscles were carefully dissected and digested in 0.2% type II collagenase for 20 minutes, and individual myofibers were dissociated by trituration (37) . Isolated myofibers were cultured in the presence or absence of R-848 (10 lg/ml) for 48 hours (in wells coated with horse serum to prevent fiber attachment) in DMEM containing 10% horse serum, 1% chick embryo extract, glutamine, and antibiotics. Fibers were retrieved 48 hours later and fixed for immunostaining. RNA extraction and quantitative reverse transcriptasepolymerase chain reaction (RT-PCR). RNA was extracted from mouse muscles and cells using TRIzol (Applied Biosystems) following the manufacturer's recommendations. Complementary DNAs (cDNAs) were prepared from 1 lg of RNA using a high-capacity cDNA Reverse Transcription kit (Applied Biosystems) according to the manufacturer's instructions. Quantitative RT-PCR was carried out using SYBR Green PCR Master Mix (Applied Biosystems) on an ABI7400 system (Applied Biosystems). Transcripts of target genes were quantified relative to the abundance of GAPDH by the change in threshold (Livak [ Statistical analysis. All data were analyzed using Student's unpaired 2-tailed t-test for comparisons between 2 groups (i.e., HisRS alone versus HisRS plus R-848) or oneway analysis of variance with Bonferroni post hoc test for multiple group comparisons. P values less than 0.05 were considered significant. Results are presented as the mean AE SD or mean AE SEM and were obtained from 1 of at least 3 independent experiments (with no significant interassay differences). In each experiment, 5 or more mice were subjected to each condition. Images shown in the figures are representative of mean data obtained in at least 3 independent experiments (using 5 or more mice per condition in each experiment, with no significant interassay differences). For in vitro data, results are from 1 of at least 3 independent experiments (with no significant interassay differences; each point was analyzed in triplicate).
RESULTS
Activation of TLR-7 or TLR-8 prolongs muscle infiltration and autoimmunity in experimental autoimmune myositis. Mouse gastrocnemius muscles injected with HisRS were substantially infiltrated by inflammatory leukocytes 4 weeks after immunization. Scattered centronucleated fibers (a sign of ongoing damage and regeneration) were also identified ( Figure 1A ). The extent of the inflammatory reaction and the cellular composition of the inflammatory infiltrate were similar at early time points in muscles injected with HisRS alone and in those injected with HisRS in the presence of the TLR agonist R-848 (HisRS plus R-848) ( Figure 1A Figure 1A ). Figure 1 shows the inflammation score in mouse gastrocnemius muscles injected with HisRS alone, HisRS plus R-848, PBS alone, or R-848 alone.
The inflammatory response in mice injected with HisRS plus R-848 did not spontaneously abate. Inflammation remained prominent at least up to 22 weeks after immunization ( Figures 1B-D) with infiltrating macrophages (CD68+ cells), T and B lymphocytes (CD3+ and B220+ cells), and areas of collagen deposition (sirius red histochemical staining) (Figure 2A ), which are typically found in the tissue of IIM patients, in perimysial and endomysial areas.
Anti-HisRS IgG antibodies were detectable in the serum of mice injected with HisRS by 1-2 weeks after immunization. Their levels progressively increased until 4-8 weeks and progressively decreased thereafter (Figure 2B) . In contrast, in mice injected with HisRS plus R-848, anti-HisRS IgG levels remained elevated in the blood up to at least 22 weeks ( Figure 2B ). The difference was consistently significant at later time points ( Figure 2B) .
Spreading of the inflammatory response to uninjected muscles after TLR-7/8 activation. The inflammation that occurred in mice immunized with HisRS alone remained confined to the injected muscles (gastrocnemius muscles). Uninjected muscles did not undergo immune cell infiltration or damage at any of the times investigated ( Figure 3A and data not shown). All of the mice that were injected with HisRS plus R-848 in the gastrocnemius muscles had infiltrating immune cells in uninjected muscles (e.g., anterior tibialis, quadriceps, or triceps brachii muscles) ( Figure 3A) . Regenerating centronucleated fibers were also sometimes identified ( Figure 3A) . Muscle inflammation was not detectable in uninjected muscles 1 week after immunization, but became evident at later time points (2 weeks), a finding compatible with an acquired immune-mediated spreading of the response.
The muscles of mice that received HisRS plus R-848 contained a significantly higher number of leukocytes than those that received HisRS alone, as assessed after isolation of CD45+ cells by immunomagnetic cell sorting ( Figure 3B) . Consistently, immunofluorescence analysis of mouse muscles after immunization revealed the presence of abundant macrophages (CD68+ cells) Figure 2C) . R-848, in the absence of HisRS, did not induce any statistically significant increment of MHC expression in uninjected muscles ( Figure 5A and data not shown).
Type I IFN is known to be produced downstream of TLR-7/8 activation and to up-regulate MHC expression Figure 5C and data not shown). Type I IFN target genes and IFNinduced proteins 44 and 27 were expressed as well (data not shown), indicating that the pathway was active upon immunization with HisRS plus R-848. Cultured myotubes also produced IFNa upon stimulation by R-848, as evaluated by ELISA ( Figure 5D ).
Type I IFN signaling is required for MHC class I expression, spreading of inflammation, and prolonged autoantibody response induced by TLR-7/8 activation. R-848 up-regulated MHC class I expression in myotubes of wild-type mouse myoblasts, as assessed by immunofluorescence and RT-PCR ( Figures 4B and C) . The effect abated in myotubes obtained from the muscles of IFNa/ bR-null mice, causally implicating the cytokine in the effect of the TLR agonist ( Figure 6A) . Accordingly, the recombinant mouse cytokine IFNa induced MHC class I in wild-type and not in IFNa/bR-null mouse myotubes (Supplementary Figure 3A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40503/abstract). MHC class I was, in contrast, as expected effectively up-regulated in response to IFNc in wild-type and IFNa/bR-null mouse myotubes (Supplementary Figure 3A) .
In vivo, MHC class I was up-regulated in uninjected muscles (quadriceps) after injection with HisRS plus R-848. Again, the effect was not detectable in IFNa/ bR-null mouse muscles ( Figure 6B ). The inflammatory reaction, evident in uninjected quadriceps muscles of wildtype mice immunized with HisRS plus R-848 ( Figure 6C ), was absent in uninjected muscles of IFNa/bR-null animals ( Figure 6C ). Numbers of CD45+ cells isolated by immunomagnetic sorting were significantly higher in wildtype than in IFNa/bR-null mouse muscles, confirming histologic data ( Figure 6C ).
Gastrocnemius muscles of wild-type and IFNa/bRnull mice injected with HisRS alone or with HisRS plus R-848 demonstrated similar levels of severe inflammation at early time points following immunization (4 weeks) (Supplementary Figure 3) . However, inflammation spontaneously abated in murine gastrocnemius muscles injected with HisRS alone, but remained severe up to 16 Figure 5 . The Toll-like receptor 7 (TLR-7)/TLR-8 agonist R-848 induces major histocompatibility complex (MHC) class I and type I interferon (IFN) expression in mice in vitro and in vivo. A, Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for MHC class I mRNA in uninjected muscles (quadriceps) of mice injected in the gastrocnemius muscles with histidyl-transfer RNA synthetase (HisRS) alone, HisRS plus R-848, phosphate buffered saline (PBS), or R-848 alone. The uninjected muscles (quadriceps) were evaluated 1 week or 2 weeks after immunization. Data were normalized to GAPDH mRNA. B, Immunofluorescence staining of uninjected muscle (quadriceps) sections isolated 1 week or 2 weeks after mice were injected in the gastrocnemius muscle with HisRS alone or HisRS plus R-848. Nuclei were revealed by Hoechst staining (blue). Results are representative of experiments in 15 or more mice (6-8 sections per mouse). Bars = 50 lm. C, IFNa mRNA detected by quantitative RT-PCR in injected muscles 1 week after mice were immunized as indicated. D, IFNa protein detected by enzyme-linked immunosorbent assay in medium culture of myotubes exposed for 24 hours to PBS or R-848. Values in A, C, and D are the mean AE SEM (n = 15 or more mice per group). * = P < 0.05; *** = P < 0.005 versus PBS. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40503/abstract. weeks after injection of gastrocnemius muscles with HisRS plus R-848 in both wild-type and IFNa/bR-null mice (Supplementary Figure 3) . This finding suggests that the long-lasting inflammatory response, which develops at the site of antigen injection in the presence of R-848, is independent of the type I IFN pathway. Serum antiHisRS IgG antibody levels, which were similar in wildtype and IFNa/bR-null mice at early time points after immunization, progressively decreased in IFNa/bR-null mice immunized with HisRS plus R-848 but remained significantly high in wild-type animals ( Figure 6D ).
TLR-7/8 IN EXPERIMENTAL MYOSITIS

DISCUSSION
IIMs comprise primarily inflammatory systemic diseases of the skeletal muscle characterized by progressive weakness, persistent tissue injury, specific and associated autoantibodies, and infiltration by T lymphocytes that recognize autoantigens expressed on myofibers (1, 10, 11) . The disease is chronic with a progressive or relapsing-remitting course (39) . Available treatments are only partially satisfactory because of our limited insight into the pathogenesis of IIM (9, 11) . Preclinical studies might provide valuable information (33) .
In this study we relied on a well-characterized model of IIM induced by intramuscular injection of the amino-terminal portion of HisRS (HisRS-induced experimental autoimmune myositis), which mimics several key features of the human disease, including the establishment of systemic humoral and cellular autoimmune response with muscle infiltration by macrophages, CD4+ and CD8+ T cells, as well as B lymphocytes (29, 30, 32, 40) . Anti-HisRS autoantibodies and injected muscle cell infiltration are already detectable 1 week after immunization (30) . The myositis induced by a single HisRS injection-unlike human IIM-is focal, with inflammation limited to the injected muscle, and transient, since autoimmunity and tissue inflammation per se abate after 7-8 weeks. This suggests that additional signals are required in vivo to reproduce key features of IIM, such as systemic involvement of the musculature and persistent production of autoantibodies against myositis-specific antigens.
Viral infection has been convincingly associated with autoimmunity, activation of TLRs, and the generation of potent adjuvant signals such as type I IFNs (15, 22, (24) (25) (26) (27) 41) . Immune complexes containing relevant myositis antigens, including HisRS, stimulate TLRs of IFN-producing cells (42) , which are found in the muscle and skin of IIM patients (43) and amplify IFN production in an autocrine manner (44) . R-848 is a well-characterized agonist of endosomal TLR-7 and TLR-8, whose activation causes type I IFN secretion (45) .
We investigated whether the presence of R-848 was sufficient to modify the natural history of the experimental myositis induced in mice. We failed to observe significant differences at early time points after immunization in terms of the severity and characteristics of muscle inflammation. At later time points, mice immunized with HisRS substantially healed. In contrast, mice immunized with HisRS plus R-848 developed a persistent myositis, which involved the originally injected muscle and unrelated muscular districts. Further studies are warranted to identify the mechanisms that cause long-lasting, diffuse inflammation in mice injected with HisRS plus R-848, but not in mice injected with HisRS alone-findings which suggest that MHC class I up-regulation is important for sustaining long-term myositis, but less critical for short-term inflammatory responses that are similar in mice immunized with HisRS alone versus HisRS plus R-848.
R-848 induced the up-regulation of myofiber MHC class I in vitro, and in vivo the myofiber expression of MHC class I molecules was up-regulated in mice immunized with HisRS plus R-848, in both injected and uninjected muscle. In particular, MHC class I molecules were already detectable in uninjected muscle, 1 week after immunization, before these muscles were infiltrated by inflammatory leukocytes. R-848 per se induced only weak MHC expression and inflammation in vivo, suggesting that antigen processing is a key regulatory event for myositis development. Proteolytic complexes that determine the repertoire of antigenic peptides, such as immunoproteasomes, are rapidly induced in infected tissue cells and are critical for priming T cell-mediated immunity. They are known to be overexpressed in the skeletal muscle of patients with IIMs, to be regulated by various cytokines, and to be a critical player in the expression of MHC class I on myofibers of IIM patients (46) . Further studies will be required to verify whether TLR-7/8 activation could induce immunoproteasome up-regulation in the presence of specific antigens and whether this event is required for the phenotypic amplification of experimental myositis following immunization with HisRS plus R-848. The systemic induction of MHC class I molecules in skeletal muscle likely plays a preparatory role, licensing the tissue for infiltration by autoreactive immune cells. recombination-activating gene 2-null mice, which lack acquired immune responses, are known to develop a severe myopathy when crossed with transgenic mice that conditionally overexpress H-2K b in muscle, indicating that even nonimmunologic events play a role. In particular, the unfolded protein response in this system is triggered as a function of the degree of MHC TLR-7/8 IN EXPERIMENTAL MYOSITISaccumulation in myofibers and elicits inflammation independently of the acquired immune response (47) .
Results obtained using our in vivo model are compatible with a mechanism in which myositis originates in a single muscle and requires both the processing of antigens as well as MHC class I up-regulation. R-848 alone per se triggers low expression of MHC class I both in vitro and in vivo at the site of injection. However, this response is not sufficient to initiate self-sustaining myositis, possibly because the extent of myofiber MHC accumulation does not reach a critical threshold level or spread to uninjected muscle groups. The combination of antigen (HisRS) and R-848, on the other hand, not only promotes the sustained expression of MHC class I at the injection site, but also leads to more widespread up-regulation of MHC class I in uninjected muscles-allowing myositis to develop as a systemic process.
The type I IFN cascade is one of the most important signaling pathways activated downstream of TLR-7/ 8. We investigated its role by eliciting experimental autoimmune myositis in IFNa/bR-null mice upon HisRS plus R-848 immunization. These mice effectively developed experimental autoimmune myositis to the same extent as wild-type mice in injected muscle, but autoantibody responses spontaneously abated and inflammation did not spread to uninjected muscles. Cultured myotubes or fibers from IFNa/bR-null mice did not up-regulate MHC class I following R-848 treatment or HisRS plus R-848 immunization. These results are consistent with previous observations about the link between TLR activation and MHC up-regulation (21, 48) and further support the involvement of type I IFN in the natural history of IIM. Of interest, not all events downstream of TLR-7/8 activation appear to be mediated via type I IFN. For example, immunization with HisRS plus R-848 elicits persistent local disease in both wild-type and IFNa/bRnull mice. These data suggest that TLR-7/8 activation at the site of HisRS injection induces signals beyond type I IFN that cause the persistence of local inflammation, consistent with previously described type I IFN-independent effects of TLR-7/8 activation (49, 50) . In contrast, sustained autoantibody responses and the spreading of inflammation to distant sites are highly dependent on type I IFN signaling pathways.
Further studies are warranted to identify the underlying molecular events downstream of TLR-7/8 in injected and uninjected muscle, but the results of the present study could provide further novel molecular targets to be used for intervention in IIM, a chronic disease that so far remains an important unmet medical need.
